Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.50 |
| ▸ | TAOK3 | Q9H2K8 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590956 | 0.94 | CA1 (0.51) | KMT2ATAOK1CA1CA2ACHE | |
| SCHEMBL5460476 | 0.90 | TAOK1 (0.50) | KMT2ATAOK1TAOK3MEN1ALDH1A1 | |
| SCHEMBL13168132 | 0.85 | CA1 (0.48) | KMT2ATAOK1CA1CA2ACHE | |
| SCHEMBL5956515 | 0.84 | MEN1 (0.48) | KMT2ACA1CA2ACHEMEN1 | |
| SCHEMBL5457149 | 0.84 | CA1 (0.48) | TAOK1CA1CA2ACHEALDH1A1 | |
| SCHEMBL5956937 | 0.83 | CTSK (0.42) | CA1CA2ACHEALDH1A1 | |
| SCHEMBL5956940 | 0.82 | EPHX1 (0.42) | KMT2ACA1CA2ACHEALDH1A1 | |
| SCHEMBL5956777 | 0.82 | POLB (0.51) | KMT2ATAOK1TAOK3MEN1 | |
| SCHEMBL5956576 | 0.81 | KMT2A (0.55) | KMT2ACA1CA2ACHEMEN1 | |
| SCHEMBL5956772 | 0.81 | KMT2A (0.55) | KMT2ACA1CA2ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | KMT2A 1253/4885TAOK1 589/4885TAOK3 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.